With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets.

LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing ...

Novo Nordisk (NVO) has released an update. Don't Miss our Black Friday Offers: Novo Nordisk has launched a share repurchase program, aiming to buy back B shares worth up to DKK 20 billion over a ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk NVO. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Novo Nordisk NOVO.B-1.53%decrease; red down pointing triangle has launched its blockbuster Wegovy weight-loss drug in China, adding the world’s second-largest economy to its growing list of ...